Histone Deacetylase Inhibitors: Overview and Perspectives

Histone deacetylase inhibitors (HDACi) comprise structurally diverse compounds that are a group of targeted anticancer agents. The first of these new HDACi, vorinostat (suberoylanilide hydroxamic acid), has received Food and Drug Administration approval for treating patients with cutaneous T-cell ly...

Full description

Saved in:
Bibliographic Details
Published in:Molecular cancer research 2007-10, Vol.5 (10), p.981-989
Main Authors: Dokmanovic, Milos, Clarke, Cathy, Marks, Paul A
Format: Article
Language:English
Subjects:
Acetylated proteins
Antineoplastic Agents - chemistry
Antineoplastic Agents - pharmacology
Antineoplastic Agents - therapeutic use
Clinical trials
Clinical Trials as Topic
Enzyme Inhibitors - chemistry
Enzyme Inhibitors - pharmacology
Enzyme Inhibitors - therapeutic use
Histone deacetylase
Histone Deacetylase Inhibitors
Histone Deacetylases - classification
Histone Deacetylases - metabolism
Humans
Metalloproteins - antagonists & inhibitors
Metalloproteins - classification
Metalloproteins - metabolism
Neoplasms - drug therapy
Neoplasms - enzymology
SAHA (suberoylanilide hydroxamic acid)
Vorinostat
Zinc - metabolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Histone deacetylase inhibitors (HDACi) comprise structurally diverse compounds that are a group of targeted anticancer agents. The first of these new HDACi, vorinostat (suberoylanilide hydroxamic acid), has received Food and Drug Administration approval for treating patients with cutaneous T-cell lymphoma. This review focuses on the activities of the 11 zinc-containing HDACs, their histone and nonhistone protein substrates, and the different pathways by which HDACi induce transformed cell death. A hypothesis is presented to explain the relative resistance of normal cells to HDACi-induced cell death. (Mol Cancer Res 2007;5(10):981–9)
ISSN:1541-7786
1557-3125
DOI:10.1158/1541-7786.MCR-07-0324